Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $363.8 million.

  • Regenxbio's Total Liabilities rose 6708.97% to $363.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $363.8 million, marking a year-over-year increase of 6708.97%. This contributed to the annual value of $206.3 million for FY2024, which is 2131.35% down from last year.
  • As of Q3 2025, Regenxbio's Total Liabilities stood at $363.8 million, which was up 6708.97% from $367.3 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Total Liabilities registered a high of $367.3 million during Q2 2025, and its lowest value of $206.3 million during Q4 2024.
  • For the 5-year period, Regenxbio's Total Liabilities averaged around $292.7 million, with its median value being $317.1 million (2022).
  • Per our database at Business Quant, Regenxbio's Total Liabilities skyrocketed by 64213.87% in 2021 and then tumbled by 2131.35% in 2024.
  • Regenxbio's Total Liabilities (Quarter) stood at $349.6 million in 2021, then fell by 9.31% to $317.1 million in 2022, then dropped by 17.3% to $262.2 million in 2023, then dropped by 21.31% to $206.3 million in 2024, then skyrocketed by 76.29% to $363.8 million in 2025.
  • Its Total Liabilities stands at $363.8 million for Q3 2025, versus $367.3 million for Q2 2025 and $216.7 million for Q1 2025.